A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

NCT06164730 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Heterozygous Familial Hypercholesterolemia
Premature Coronary Heart Disease

Interventions

DRUG: VERVE-102

Sponsor

Verve Therapeutics, Inc.